{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:04:20Z","timestamp":1788519860708,"version":"build-2803163510"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Neurosci."],"abstract":"<jats:p>Ziconotide is a non-opioid analgesic that acts on N-type voltage-gated calcium channels. Despite its proven effectiveness in pain treatment, it can induce neuropsychiatric symptoms. The aim of this article is to present a case of psychosis secondary to ziconotide and to explore the variety of neuropsychiatric symptoms it produces, exploring the relationship between these symptoms and the mechanism of action of ziconotide. For this purpose, a clinical case is presented as well as a scoping review of other cases published in the scientific literature. A search on Web of Science, Pubmed and Embase databases was performed on December 11, 2023, following the criteria of the PRISMA-ScR Statement. The clinical case presented shows the variety of neuropsychiatric symptomatology that ziconotide can cause in the same patient. On the other hand, 13 papers were retrieved from the scoping review (9 case reports, 4 case series), which included 21 cases of patients treated with ziconotide who presented adverse effects ranging from psychotic symptoms to delirium. In conclusion, the variety of neuropsychiatric symptoms derived from ziconotide could be related to the blockade of N-type voltage-gated calcium channels in glutamatergic and GABAergic neurons, in turn affecting dopaminergic pathways.<\/jats:p>","DOI":"10.3389\/fnmol.2024.1412855","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T13:34:48Z","timestamp":1729085688000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Ziconotide and psychosis: from a case report to a scoping review"],"prefix":"10.3389","volume":"17","author":[{"given":"Marc","family":"Peraire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Gimeno-Vergara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Pick-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Bosc\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"Echeverria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.neurom.2022.02.146","article-title":"A case of prolonged psychosis with intrathecal ziconotide","volume":"25","author":"Abdelsayed","year":"2022","journal-title":"Neuromodulation Technol. Neural Interface"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.3390\/ijms20143537","article-title":"Genetic associations between voltage-gated calcium channels and psychiatric disorders","volume":"20","author":"Andrade","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.33588\/rn.5201.2010475","article-title":"Efectos adversos neuropsiqui\u00e1tricos del ziconotide intratecal","volume":"52","author":"Ayuga-Loro","year":"2011","journal-title":"Rev. Neurol."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.bpsc.2020.06.018","article-title":"The cannabinoid CB1 receptor in schizophrenia","volume":"6","author":"Borgan","year":"2021","journal-title":"Biol. Psychiatry Cogn. Neurosci Neuroimaging"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s13643-017-0644-y","article-title":"Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study","volume":"6","author":"Bramer","year":"2017","journal-title":"Syst. Rev."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2174\/1570159x14666160210142056","article-title":"Ziconotide monotherapy: a systematic review of randomised controlled trials","volume":"15","author":"Brookes","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.9740\/mhc.2018.09.242","article-title":"Ziconotide-induced psychosis: a case report and literature review","volume":"8","author":"Burdge","year":"2018","journal-title":"Mental Health Clin."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13041-022-00982-z","article-title":"Regulation of N-type calcium channels by nociceptin receptors and its possible role in neurological disorders","volume":"15","author":"Caminski","year":"2022","journal-title":"Mol. Brain"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.schres.2018.02.049","article-title":"Similar psychotic and cognitive profile between ketamine dependence with persistent psychosis and schizophrenia","volume":"199","author":"Cheng","year":"2018","journal-title":"Schizophr. Res."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1177\/0269881116650087","article-title":"Prediction error, ketamine and psychosis: an updated model","volume":"30","author":"Corlett","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/1741-7015-11-126","article-title":"Toward the future of psychiatric diagnosis: the seven pillars of RDoC","volume":"11","author":"Cuthbert","year":"2013","journal-title":"BMC Med."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40120-015-0035-z","article-title":"Intrathecal ziconotide and morphine for pain relief: a case series of eight patients with refractory cancer pain, including five cases of neuropathic pain","volume":"4","author":"de la Calle Gil","year":"2015","journal-title":"Neurol. Therapy"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.neuron.2019.03.013","article-title":"Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments","volume":"102","author":"Duman","year":"2019","journal-title":"Neuron"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.2174\/138920112800784961","article-title":"The glutamate hypothesis of schizophrenia: neuroimaging and drug development","volume":"13","author":"Egerton","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/schbul\/sbr180","article-title":"Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F\/(11)C]-DOPA PET studies","volume":"39","author":"Fusar-Poli","year":"2013","journal-title":"Schizophr. Bull."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.5334\/tohm.431","article-title":"Ziconotide-induced Oro-lingual dyskinesia: 3 cases","volume":"10","author":"Grajny","year":"2020","journal-title":"Tremor Other Hyperkinetic Mov."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"097","DOI":"10.1093\/sleep\/zsac097","article-title":"Proteomic biomarkers of Kleine-Levin syndrome","volume":"45","author":"H\u00e9dou","year":"2022","journal-title":"Sleep"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/j.1533-2500.2009.00289.x","article-title":"Intrathecal ziconotide for complex regional pain syndrome: seven case reports","volume":"9","author":"Kapural","year":"2009","journal-title":"Pain Practice"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.schres.2014.10.007","article-title":"Anti-NMDA receptor encephalitis, autoimmunity, and psychosis","volume":"176","author":"Kayser","year":"2016","journal-title":"Schizophr. Res."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1176\/appi.psy.43.1.63","article-title":"Intractable delirium associated with ziconotide successfully treated with electroconvulsive therapy","volume":"43","author":"Levin","year":"2002","journal-title":"Psychosomatics"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ceca.2009.07.007","article-title":"Dual modulation of CNS voltage-gated calcium channels by cannabinoids: focus on CB1 receptor-independent effects","volume":"46","author":"Lozovaya","year":"2009","journal-title":"Cell Calcium"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.jagp.2013.09.005","article-title":"Neuropathogenesis of delirium: review of current etiologic theories and common pathways","volume":"21","author":"Maldonado","year":"2013","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"198","DOI":"10.2174\/1570159x14666160224124446","article-title":"The proteomics of intrathecal analgesic agents for chronic pain","volume":"15","author":"Moore","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/s41380-018-0252-9","article-title":"Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies","volume":"24","author":"Moriguchi","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/pme.12005","article-title":"Prolonged delirium with psychotic features from omega conotoxin toxicity","volume":"14","author":"Obafemi","year":"2013","journal-title":"Pain Med."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"609","DOI":"10.5664\/jcsm.9058","article-title":"Kleine-Levin syndrome, GABA, and glutamate","volume":"17","author":"Ortega-Alb\u00e1s","year":"2021","journal-title":"J. Clin. Sleep Med."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/s0304-3959(99)00254-7","article-title":"Adverse effects associated with the intrathecal administration of ziconotide","volume":"85","author":"Penn","year":"2000","journal-title":"Pain"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"97.e11","DOI":"10.1016\/j.genhosppsych.2014.10.001","article-title":"Ziconotide-induced psychosis: a case report","volume":"37","author":"Phan","year":"2015","journal-title":"Gen. Hosp. Psychiatry"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1525-1403.2011.00334.x","article-title":"Psychiatric predisposition to autonomic and abnormal perception side-effects of ziconotide: a case series study","volume":"14","author":"Poli","year":"2011","journal-title":"Neuromodulation"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2147\/tcrm.s4438","article-title":"Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain","volume":"5","author":"Smith","year":"2009","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.jpain.2014.01.297","article-title":"Analgesia and psychosis: intrathecal ziconotide in a young hospice patient with spinocerebellar ataxia and painful peripheral neuropathy","volume":"15","author":"Stewart","year":"2014","journal-title":"J. Pain"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"100086","DOI":"10.1016\/j.pmip.2021.100086","article-title":"Ziconotide-induced psychosis in patient without previous psychiatric history: a case report","author":"Su","year":"2021","journal-title":"Pers. Med. Psychiatry"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"7958","DOI":"10.1523\/JNEUROSCI.0247-14.2014","article-title":"Presynaptic calcium channel inhibition underlies CB\u2081 cannabinoid receptor-mediated suppression of GABA release","volume":"34","author":"Szab\u00f3","year":"2014","journal-title":"J. Neurosci."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1111\/pme.12666","article-title":"The relationship between the mechanisms of action and safety profiles of intrathecal morphine and ziconotide: a review of the literature","volume":"16","author":"Webster","year":"2015","journal-title":"Pain Med."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3928\/00485713-20150212-02","article-title":"Ziconotide-associated psychosis treated with invega","volume":"45","author":"Whitlow","year":"2015","journal-title":"Psychiatr. Ann."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1124\/pr.114.009654","article-title":"The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential","volume":"67","author":"Zamponi","year":"2015","journal-title":"Pharmacol. Rev."}],"container-title":["Frontiers in Molecular Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnmol.2024.1412855\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T13:34:49Z","timestamp":1729085689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnmol.2024.1412855\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":36,"alternative-id":["10.3389\/fnmol.2024.1412855"],"URL":"https:\/\/doi.org\/10.3389\/fnmol.2024.1412855","relation":{},"ISSN":["1662-5099"],"issn-type":[{"value":"1662-5099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]},"article-number":"1412855"}}